• Home  / 
  • News
  •  /  Entering the age of the $1 million medicine

Entering the age of the $1 million medicine

Reuters analysis talks about drug development for what they call “orphan diseases”, which are those relating to very small segments of the population.

Because only a small percentage of the population has these problems, drug companies have been able to charge what they like. Rare diseases therefore are attracting a lot of attention from various pharma players.

It seems though that health care providers are rebelling and the pressure is on to shake out pricing

Analysis: Entering the age of the $1 million medicine | Reuters.

Click here to add a comment

Leave a comment: